logo-loader

Faron Pharmaceuticals focused on fighting cancers via novel immunotherapies

Last updated: 08:22 18 Mar 2024 EDT, First published: 05:30 08 Feb 2024 EST

Snapshot

  • Faron Pharma rallies 28% following ‘remarkable’ Phase 1 data
  • Faron Pharmaceuticals enjoys momentum as COVID-19 drug candidate gets green light for late-stage trials
  • Faron Pharma data readout should provide more clarity - broker
  • Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study
cancer

About the company

Faron Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Finland and the United States, with a focus on developing bexmarilimab, a first-in-class, humanized antibody that binds the Clever-1 target on myeloid cells and macrophages.

Clever-1 is an immunosuppressive receptor that promotes tumour growth and metastases when expressed on macrophages

Bexmarilimab primes the tumour microenvironment for optimal antitumour immune responses, in both hematological malignancies and solid tumours.

How it is doing

18 Mar 2024

Faron Pharmaceuticals Limited (AIM:FARN) shares rallied more than 28% on Monday after disclosing some “truly remarkable” data from the phase I portion of an ongoing cancer study.

Researchers are assessing the potential of bexmarilimab immunotherapy and chemotherapy when used to treat myelodysplastic syndrome (MDS), a blood-borne cancer; specifically in a group that has failed to respond to hypomethylating agents (HMAs).

The latest update showed that four out of the initial five phase I patients were still alive after eight months of follow-up, a survival benefit that stands out compared to current treatments.

Faron’s shares were swapping for 180p as of 12.20pm, compared to the last close at 140p.

18 Mar 2024

Faron Pharmaceuticals Limited (AIM:FARN)'s chief executive Dr Markku Jalkanen has described the latest data from the phase I portion of the BEXMAB study as 'truly remarkable'.

Researchers are assessing the potential of bexmarilimab when used to treat myelodysplastic syndrome (MDS), a blood-borne cancer; specifically in a group that has failed to respond to hypomethylating agents (HMAs).

13 Mar 2024

Faron Pharmaceuticals Limited (AIM:FARN) said the "excellent data" from its BEXMAB trial of cancer drug bexmarilimab has "intensified numerous ongoing partnering discussions", which it will advance over the coming year.

The trial was particularly significant as it targeted a patient group with MDS, an aggressive form of leukaemia that typically has limited treatment options. The early cohort comprised 10 and was split into two: higher-risk frontline MDS patients and those who had failed to respond to hypomethylating agents (HMAs).

Insight: Faron Pharmaceuticals enjoys momentum as COVID-19 drug candidate gets green...

26 Jan 2021

Faron Pharmaceuticals Oy (LON:FARN) is enjoying momentum with its project pipeline as its COVID-19 candidate Traumakine has just received the green light to enter the final stage of trials in the US.

The Finnish drugmaker will test it on people who have been hospitalised but do not yet need ventilation and have not received corticosteroids.

What the brokers say

15 Mar 2024

Faron Pharmaceuticals Limited (AIM:FARN) will release updated results from its BEXMAB clinical study of its drug bexmarilimab next Tuesday (Mar 19) with analysts and investors keenly eyeing disease progression data from patients with myelodysplastic syndromes (MDS), a type of blood cancer.

Panmure Gordon in a research note pointed out the median survival rate for people with the refractory form of the disease is four to six months.

It pointed out that three out of four members of a cohort – those that didn’t respond to a treatment called a hypomethylating agent – had already shown “above median survival”.

What management says

18 Mar 2024

Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients failed on previous hypomethylating agent (HMA).

Dr Jalkanen said the study demonstrated promising results in reducing cancer cells and extending life expectancy in patients. He highlighted the durability and effectiveness of the treatment, particularly in patients with a severe form of myeloid leukemia called MDS, where current treatment options are limited.

Dr Jalkanen said the Phase 1 results showed a high overall response rate and an extended overall survival rate among patients, which could lead to a new treatment option for an underserved patient population. He emphasized the importance of continuing the study and engaging with regulators to bring the treatment to market as swiftly as possible. He also noted the potential for increased interest from other pharmaceutical companies based on the positive data released.

Faron Pharmaceuticals outlines groundbreaking work in cancer treatment -...

Dr. Markku Jalkanen, CEO of Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), delivered a pivotal presentation on the company's groundbreaking work in cancer treatment, focusing on the reprogramming of myeloid cells to combat cancer at the Proactive One2One Investor Conference. Myeloid...

on 02/01/2024